Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OATD-01

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Galapagos

            Deal Size: $380.8 million Upfront Cash: $29.7 million

            Deal Type: Licensing Agreement November 05, 2020

            Details:

            OncoArendi Therapeutics gains global development and commercialization rights of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase inhibitor to treat Idiopathic pulmonary fibrosis and other diseases with a fibrotic component.